Lianhuan Pharmaceutical announced that the company recently received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for the active drug bilastine issued by the State Drug Administration. The API has passed the review and approval, and the registration status is “A”. The company submitted an application for technical review of bilastine APIs in 2025, with a total R&D investment of about 5.377,700 yuan. As of the date of disclosure of the announcement, there were 18 registration numbers for bilastine APIs, 7 of which had a registration status of “A”. The above matters are not expected to have a significant impact on the company's recent operating results.

Zhitongcaijing · 2d ago
Lianhuan Pharmaceutical announced that the company recently received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for the active drug bilastine issued by the State Drug Administration. The API has passed the review and approval, and the registration status is “A”. The company submitted an application for technical review of bilastine APIs in 2025, with a total R&D investment of about 5.377,700 yuan. As of the date of disclosure of the announcement, there were 18 registration numbers for bilastine APIs, 7 of which had a registration status of “A”. The above matters are not expected to have a significant impact on the company's recent operating results.